婴儿急性淋巴细胞白血病分子生物学特征及治疗进展  

Molecular biological characteristics and treatment advances in infant acute lymphoblastic leukemia

作　　者：覃远玲 李天宇 Yuanling Qin;Tianyu Li(Department of Hematology,Affiliated Wuxi People's Hospital of Nanjing Medical University,Wuxi Children's Hospital,Wuxi 214000,China)

机构地区：[1]南京医科大学附属无锡人民医院、无锡市儿童医院血液科,214000

出　　处：《国际儿科学杂志》2024年第4期265-269,共5页International Journal of Pediatrics

基　　金：江苏省卫健委A类重点项目(ZDA2020013);无锡市卫健委太湖人才计划(YXTD202101);江苏省医学会科研专项资金(SYH-32034-0084,20230031)。

摘　　要：婴儿急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)具有与其他年龄段患儿不同的临床表现、分子遗传学特征及预后。目前,婴儿ALL的治疗仍以常规化疗、造血干细胞移植为主,但早期复发率高,总体生存率低,疗效欠佳。近年来的多项大型临床试验进一步探讨了其分子生物学特征,优化了危险分层,但传统治疗方法未能明显改善这类患儿的预后。临床研究表明采用免疫治疗、靶向药物治疗可明显提高患儿生存率。该文主要总结婴儿ALL的分子生物学特征、临床研究结果、治疗方法以及未来可能的治疗靶点。Infant acute lymphoblastic leukemia(ALL)differs from those of children in other age groups in terms of its clinical manifestations,molecular hereditary characteristics,and prognosis.The treatment of ALL in infants is still mainly based on conventional chemotherapy and hematopoietic stem cell transplantation,but the prognosis is poor due to its high early relapse and low overall survival rate.In recent years,several large-scale clinical trials have further explored its molecular biological characteristics and optimized risk stratification,but traditional treatments have failed to significantly improve the prognosis of these children.New clinical trials have demonstrated that immunotherapy and targeted drugs could greatly improve infant survival.This article summarizes the molecular biological features,clinical research findings,therapeutic approaches,and potential therapeutic targets for infant ALL.

关 键 词：急性淋巴细胞白血病 婴儿 KMT2A基因重排 免疫治疗 靶向治疗 

分 类 号：R733.71[医药卫生—肿瘤]